SCHEMBL6408949

SCHEMBL6408949

CN1CCC(=O)C(C2c3ccccc3Oc3ccccc32)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
DRD2 P14416 1/20 0.47
GABRA1 P14867 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
DRD4 P21917 1/20 0.47
SLC6A2 P23975 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
HRH1 P35367 1/20 0.47
ADRA1B P35368 1/20 0.47
DRD3 P35462 1/20 0.47
HTR2B P41595 1/20 0.47
HTR3A P46098 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411557 0.82 SIGMAR1 (0.49) DRD2DRD1DRD4HTR2ADRD3
SCHEMBL6408807 0.81 GAA (0.42) CHRM2GAAHRH2MAPTCYP3A4
SCHEMBL6409793 0.81 BRD4 (0.41) CHRM2HTR1AADRA2ADRD2ADRA2B
SCHEMBL6411932 0.80 ADRA2A (0.46) CHRM2HTR1AADRA2ADRD2ADRA2B
SCHEMBL6406919 0.78 TACR1 (0.51) DRD2DRD3GAASIGMAR1KMT2A
SCHEMBL4253544 0.74 HTR2A (0.73) CHRM2HTR1AADRA2ADRD2GABRA1
SCHEMBL1146217 0.74 HTR2A (0.73) CHRM2HTR1AADRA2ADRD2GABRA1
SCHEMBL12072060 0.74 HTR2A (0.73) CHRM2HTR1AADRA2ADRD2GABRA1
SCHEMBL3716425 0.74 HTR2A (0.73) CHRM2HTR1AADRA2ADRD2GABRA1
SCHEMBL12856888 0.74 HTR2A (0.73) CHRM2HTR1AADRA2ADRD2GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 CHRM2 313/4885HTR1A 172/4885ADRA2A 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.